Generic Drug News and Research

RSS

Generic Drugs are official nonbrand names by which medicines are known. Generic names usually refer to the chemical name of the drug.

New computer model helps study cell membrane dynamics

A cell constantly remodels its fluid membranes to carry out critical tasks, such as recognizing other cells, getting nutrients or sorting proteins.

9 Apr 2008

Two drug combo blood pressure therapy lowers cardiovascular risk

An international blood pressure study comparing two single-pill drug combinations has yielded results so significant that the study has been stopped early and the researchers say their findings might alter the way high blood pressure is treated worldwide.

1 Apr 2008

University of Kentucky physician revolutionizes gene research

A dramatic new study published in the most recent issue of Nature questions some of the mechanisms underlying a new class of drugs based on Nobel Prize-winning work designed to fight diseases ranging from macular degeneration to diabetes.

28 Mar 2008

Free drug samples may burden patients' pockets

Following free drug sample receipt, patients who receive these samples have significantly higher out-of-pocket prescription costs than those who don't, according to the first study to look at the out-of-pocket cost associated with free-sample use, published in the March 24, 2008, issue of Medical Care.

25 Mar 2008

Robot fetches objects with just a point and a click

Robots are fluent in their native language of 1 and 0 absolutes but struggle to grasp the nuances and imprecise nature of human language.

20 Mar 2008

NicOx signs agreement for commercial manufacture of Naproxcinod drug substance

NicOx S.A. (Euronext Paris: COX) has announced it has signed an agreement with the fine chemical company Archimica, for the commercial manufacturing and supply of naproxcinod drug substance (or active pharmaceutical ingredient, API).

20 Mar 2008

Genomas awarded $1.2 million to develop DNA-guided system for management of statin therapy

Genomas, a biomedical company advancing DNA-guided medicine and personalized healthcare, has announced the award of a Fast-Track Phase I-II Small Business Innovation Research (SBIR) Grant totaling $1.2 million.

20 Mar 2008

Watson Pharmaceuticals files application for generic LYBREL

Watson Pharmaceuticals, Inc. has confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its Levonorgestrel and Ethinyl Estradiol tablets, USP (0.09 mg/0.02 mg) extended-cycle oral contraceptive product prior to the expiration of patents owned by Wyeth.

14 Mar 2008

Barr Pharmaceuticals receives approval for generic Taxol injection

Barr Pharmaceuticals, Inc. announced that its subsidiary, PLIVA - Lachema a.s., has received final approval from the U.S. Food and Drug Administration (FDA) for its generic version of Bristol-Myers Squibb Company's Taxol (paclitaxel) Injection USP, 6mg/mL, packaged in 100mg/16.7 mL and 300mg/50 mL Multiple-dose Vials.

13 Mar 2008

Once-a-week arthritis pill significantly reduces the risk of heart attacks

A once-a-week pill to treat rheumatoid arthritis significantly reduces the risk of heart attack and stroke for people with the painful joint condition.

10 Mar 2008

Watson Pharmaceuticals files application for generic SEASONIQUE

Watson Pharmaceuticals, Inc. has confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its levonorgestrel and ethinyl estradiol (0.15 mg/0.03 mg) extended-cycle oral contraceptive product, prior to the expiration of patents owned by Duramed Pharmaceuticals, Inc., a subsidiary of Barr Pharmaceuticals, Inc.

6 Mar 2008

Costly placebo works better than cheap one

A 10-cent pill doesn't kill pain as well as a $2.50 pill, even when they are identical placebos, according to a provocative study by Dan Ariely, a behavioral economist at Duke University.

6 Mar 2008

Barr Pharmaceuticals announces favorable ruling in Yasmin patent case

Barr Pharmaceuticals, Inc. has announced that the U.S. District Court for the District of New Jersey has ruled in favor of its subsidiary, Barr Laboratories, Inc., in the challenge of the patent listed by Bayer Schering Pharma, AG in connection with Bayer Schering's Yasmin(R) (drospirenone and ethinyl estradiol) oral contraceptive.

4 Mar 2008

AstraZeneca submits sNDA for SEROQUEL XR for treatment of major depressive disorder

AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for once- daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of major depressive disorder (MDD) as monotherapy, adjunct therapy, and maintenance therapy in adult patients.

1 Mar 2008

Stress and fear affects cancer's recurrence

After the surgical removal of a malignant tumor, the chance that cancer will re-appear in a different location of the body remains high.

28 Feb 2008

Forest Laboratories to develop and distribute the novel beta blocker Bystolic (nebivolol)

Mylan Inc. has announced that it and Forest Laboratories Holdings, Ltd., a wholly owned subsidiary of Forest Laboratories, Inc. have amended their January 2006 agreement to commercialize, develop and distribute the novel beta blocker Bystolic (nebivolol), which is currently approved in the United States for the treatment of hypertension.

28 Feb 2008

Barr confirms Avodart patent challenge

Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by GlaxoSmithKline in connection with its Avodart(R) (dutasteride) soft gelatin capsules, 0.5mg.

27 Feb 2008

Multiple approaches to type 1 diabetes

Type 1 diabetes, formerly called insulin-dependent diabetes, juvenile diabetes or childhood-onset diabetes, affects 1 to 2 million people in the U.S. and millions more worldwide.

21 Feb 2008

Many U.S. consumers want overhaul of health care design, delivery

American consumers want more from their health care system than they're currently getting - greater online connection to health care providers and medical records, customized insurance coverage and wider access to emerging innovations such as retail clinics, a new survey from Deloitte reveals.

21 Feb 2008

Barr receives approval for generic Mirapex tablets

Barr Pharmaceuticals, Inc. has announced that its subsidiary, Barr Laboratories, Inc., has received final approval from the U.S. Food and Drug Administration (FDA) for its generic version of Boehringer Ingelheim Pharmaceuticals, Inc.'s Mirapex Tablets (Pramipexole Dihydrochloride) 0.125mg, 0.25mg, 0.5mg, 1mg & 1.5mg.

20 Feb 2008